This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hintzen, R Q Search for Related Content PubMed PubMed Citation Articles by Hintzen, R Q Social Bookmarking                         What's this?

Stem cell transplantation in multiple sclerosis: multiple choices and multiple challengesy

Department of Neurology, Erasmus Medical Centre Rotterdam, PB 2040, Rotterdam 3000 CA, The Netherlands, rhintzen{at}xs4all.nl

Multiple sclerosis (MS) is generally considered as an autoimmune disease of the central nervous system. This concept has led to the idea that profound immunosuppression followed by transplantation of stem cell grafts would stop, or at least slow down, disease activity. Supported by the positive effects of hematopoietic stem cell transplantation (HSCT) on experimental autoimmune encephalomyelitis and by anecdotal reports on the beneficial effect of HSCT on MS patients with concomitant malignant disease, HSCT programs for MS have been initiated worldwide. At this stage, it is impossible to draw general conclusions from the preliminary data reported and therefore overenthusiastic expectations should be tempered. The follow-up periods are too short, the groups are too small, the selected patients and protocols too heterogeneous, and publication bias on positive results cannot be excluded. However, there is ample evidence that HSCT is a technically feasible approach in MS, not more dangerous than in the hemato-oncological diseases. For every step in the HSCT procedure, there are many different options. The time has come for a systematic analysis of the safety and efficacy associated with the different methodologies.

Key Words: autoimmune disease • bone marrow transplantation • immunosuppression • multiple sclerosis • stem cell transplantation

Multiple Sclerosis, Vol. 8, No. 2, 155-160 (2002)
DOI: 10.1191/1352458502ms789oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J Fagius, J Lundgren, and G Oberg Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation Multiple Sclerosis, February 1, 2009; 15(2): 229 - 237. [Abstract] [PDF]

				T Mondria, C H J Lamers, P A W t. Boekhorst, J W Gratama, and R Q Hintzen Bone-marrow transplantation fails to halt intrathecal lymphocyte activation in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, September 1, 2008; 79(9): 1013 - 1015. [Abstract] [Full Text] [PDF]

				J P A Samijn, P A W te Boekhorst, T Mondria, P A van Doorn, H Z Flach, F G A van der Meche, J Cornelissen, W C Hop, B Lowenberg, and R Q Hintzen Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis J. Neurol. Neurosurg. Psychiatry, January 1, 2006; 77(1): 46 - 50. [Abstract] [Full Text] [PDF]